A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

July 16, 2024

Study Completion Date

July 16, 2024

Conditions
SarcomaLiposarcomaLeiomyosarcomaUndifferentiated Pleomorphic Sarcoma
Interventions
DRUG

Eribulin

The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).

DRUG

Pembrolizumab

The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.

Trial Locations (2)

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

NCT03899805 - A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | Biotech Hunter | Biotech Hunter